MIF inhibition interferes with the inflammatory and T cell-stimulatory capacity of NOD macrophages and delays autoimmune diabetes onset by Korf, Hannelie et al.
RESEARCH ARTICLE
MIF inhibition interferes with the
inflammatory and T cell-stimulatory capacity
of NOD macrophages and delays
autoimmune diabetes onset
Hannelie Korf1¤*, Laura Breser2, Jelter Van Hoeck1, Janet Godoy2, Dana P. Cook1,
Benoit Stijlemans3,4, Elien De Smidt1, Carolien Moyson1, João Paulo Monteiro Carvalho
Mori Cunha1, Virginia Rivero2, Conny Gysemans1☯, Chantal Mathieu1☯
1 Laboratory of Clinical and Experimental Endocrinology (CEE), Department of Chronic Diseases,
Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium, 2 Center for Research in Clinical
Biochemistry and Immunology, Department of Clinical Biochemistry, National University of Cordoba,
Cordoba, Argentina, 3 Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Brussels,
Belgium, 4 Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium
☯ These authors contributed equally to this work.
¤ Current address: Laboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing
(CHROMETA), KU Leuven, Leuven, Belgium
* hannelie.korf@kuleuven.be
Abstract
Macrophages contribute in the initiation and progression of insulitis during type 1 diabetes
(T1D). However, the mechanisms governing their recruitment into the islets as well as the
manner of retention and activation are incompletely understood. Here, we investigated a
role for macrophage migration inhibitory factor (MIF) and its transmembrane receptor,
CD74, in the progression of T1D. Our data indicated elevated MIF concentrations especially
in long-standing T1D patients and mice. Additionally, NOD mice featured increased MIF
gene expression and CD74+ leukocyte frequencies in the pancreas. We identified F4/80+
macrophages as the main immune cells in the pancreas expressing CD74 and showed that
MIF antagonism of NOD macrophages prevented their activation-induced cytokine produc-
tion. The physiological importance was highlighted by the fact that inhibition of MIF delayed
the onset of autoimmune diabetes in two different diabetogenic T cell transfer models.
Mechanistically, macrophages pre-conditioned with the MIF inhibitor featured a refractory
capacity to trigger T cell activation by keeping them in a naïve state. This study underlines a
possible role for MIF/CD74 signaling pathways in promoting macrophage-mediated inflam-
mation in T1D. As therapies directed at the MIF/CD74 pathway are in clinical development,
new opportunities may be proposed for arresting T1D progression.
PLOS ONE | https://doi.org/10.1371/journal.pone.0187455 November 2, 2017 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Korf H, Breser L, Van Hoeck J, Godoy J,
Cook DP, Stijlemans B, et al. (2017) MIF inhibition
interferes with the inflammatory and T cell-
stimulatory capacity of NOD macrophages and
delays autoimmune diabetes onset. PLoS ONE 12
(11): e0187455. https://doi.org/10.1371/journal.
pone.0187455
Editor: Paolo Fiorina, Children’s Hospital Boston,
UNITED STATES
Received: June 2, 2017
Accepted: October 22, 2017
Published: November 2, 2017
Copyright: © 2017 Korf et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by grants from
the Flemish Research Foundation (Fonds Voor
Wetenschappelijk Onderzoek Vlaanderen
G.0649.08, G.0734.10 and 1.5.118.13N, a doctoral
fellowhip to D.P.C., a postdoctoral fellowship to H.
K., and a clinical fellowship to C.M.), the Belgium
Program on Interuniversity Poles of Attraction
Introduction
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease characterized by the specific
destruction of insulin-producing β cells in the pancreatic islets of Langerhans. Apart from T
cells, it has become increasingly clear that also other immune cells such as macrophages, den-
dritic cells, B cells, NK and NK-T cells as well as β cells themselves contribute towards T1D
pathogenesis [1]. Macrophages in particular are recognized as the first cells to infiltrate the
islets, lingering there due to abnormal adhesion molecule profiles [2–4]. They play a critical
effector role in diabetes development, attributed primarily to the elevated production of
inflammatory cytokines and other cytotoxic parameters [2,4–8]. This pro-inflammatory signa-
ture of T1D-associated macrophages may explain their defective capacity to clear apoptotic
cells silently as well as their preferential ability to stimulate diabetogenic effector T cells rather
than regulatory cells [9,10].
Factors which orchestrate the recruitment of macrophages to the islets may include a wide
array of chemokines as well as macrophage migration inhibitory factor (MIF). MIF has been
identified as an upstream activator of the innate immune response which mediates the recruit-
ment and retention of monocytes/macrophages by binding to the CD74/CD44 receptor com-
plex [11]. Its pleiotropic actions include inhibition of apoptosis [12], activation of p44/p42
MAPK signaling [13], promotion of pro-inflammatory mediators such as TNFα, NO and
PGE2 [11,13,14], negative regulation of the immunosuppressive effects of endogenous gluco-
corticoids [15], and the recruitment of leukocytes to sites of inflammation [16]. In line with
this, MIF has been implicated in the progression of many inflammatory and autoimmune dis-
eases such as rheumatoid arthritis, asthma, sepsis, inflammatory bowel disease, systemic lupus
erythematosus, and cancer. [17–21]. In T1D, the pathogenic contribution of MIF was reported
by studies demonstrating that antibody and pharmacological inhibitor-mediated MIF neutrali-
zation had a prophylactic effect on accelerated diabetes models. Furthermore, development of
multiple low-dose streptozotocin (MLD-STZ)-induced diabetes could be suppressed in mice
deficient for MIF, suggesting that MIF is a key player in the development of immune-mediated
diabetes [22,23]. Although these studies suggest an interesting association for MIF with T1D
progression, they are limited in pinpointing the precise mechanisms for MIF in disease patho-
genesis. Furthermore, it remains unclear whether the protection against disease onset by tar-
geting MIF in these cases was not merely a result of dampening the acute inflammatory events
triggered by the diabetes-inducing/accelerating chemical agents. As such the question of
whether MIF targeting strategies interfere in the underlying auto-reactive T cell response is left
largely unexplored. Here, we assessed the physiological relevance of MIF in spontaneous auto-
immune diabetes in NOD mice and in human T1D disease by comprehensively assessing cir-
culating and local (pancreatic) MIF levels as well as the transmembrane expression of CD74
on circulating human T1D monocytes and murine pancreatic diabetes-prone NOD macro-
phages. We further tested whether inhibition of MIF using a small molecule inhibitor, isoxazo-
lines (ISO-1), could delay autoimmune diabetes onset in vivo and investigate possible
mechanisms which may account for its disease modifying properties.
Research design and methods
Human subjects and samples
Control individuals were recruited from the general population at the KU LEUVEN (Leuven,
Belgium). Patients with established T1D diagnosed on the basis of clinical criteria [24] were
recruited from the clinical department of Endocrinology at the University Hospital Leuven.
This study was approved by the institutional ethical board of the University hospital Leuven
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(S52697) and informed consent was obtained from every subject. Heparin-coated tubes (BD
Biosciences, Erembodegem, Belgium) were used to collect peripheral blood for serum and
peripheral blood mononuclear cells (PBMCs) isolation. The clinical characteristics for the
patients have been summarized in S1 Table.
Animals
C57BL/6 (C57BL/6/6NHsd; H-2b) mice were purchased from Harlan (Horst, The Nether-
lands) and NOD mice were bred and housed under semi-barrier conditions in our animal
facility at KU LEUVEN (Leuven, Belgium). OT-II transgenic (Tg) mice which carry the MHC
class II-restricted Tg TCR for OVA323-339 were kindly provided by Prof. Moser (ULB, Brussels,
Belgium) and further bred in our animal facility. BDC2.5 TCR Tg NOD mice and NOD.SCID
mice were bred from stocks originally purchased from the Jackson Laboratory (Bar Harbor,
ME). Animals were maintained according to the National Institutes of Health (NIH) Guide for
the Care and Use of Laboratory Animals, and all experimental procedures were approved and
performed in accordance with the Ethics Committee of the KU LEUVEN (P135-2010).
Phenotypic analysis of human T1D monocytes
PBMCs isolated from peripheral blood of human T1D patients and age-matched controls were
stained with the following antibodies: CD3, CD14, CD16, CD19, CD56, CD74, and HLA-DR
(all eBioscience, San Diego, CA) and matching isotype controls. Non-viable cells were
excluded by using the fixable Live/Dead Yellow stain (Invitrogen) and monocytes were further
defined as previously described [25]. Data acquisition was performed on a Gallios™ flow
cytometer (Beckman Coulter, Analis, Suarle´e, Belgium) and analyzed using FlowJo™ software
(Treestar, Ashland, OR). For intracellular staining, PBMCs were stimulated with LPS and bre-
feldin A (eBioscience) for 18 h and then stained with the same antibody cocktail as described
above followed by the addition of Cytofix/Cytoperm (eBioscience) and anti-human TNFα
(eBioscience).
Real-time quantitative polymerase chain reaction (qPCR)
Total RNA was extracted from homogenized pancreas tissue. A constant amount of RNA was
reverse transcribed and the qPCR amplification reaction was performed as previously
described [26]. MIF primers sequence: FW 5’-CGGACCGGGTCTACATCAAC-3’; RW 5’-
GAACAGCGGTGCAGGTAAGTG-3’; (Eurogentec, Liège, Belgium). For mouse CD74 we used
pre-designed primers from Integrated DNA Technologies (IDT), Coralville, IA using Fast
SYBR1 Green Master Mix in combination with TaqMan1 Fast Universal Master Mix
(Thermo Fisher Scientific/Invitrogen, Waltham, MA). All samples were normalized to the geo-
metrical mean of ribosomal protein L27 (rpl27) (primers: FW 5’-GTCGAGATGGGCAAGT
TCAT-3’; RW 5’-TTCTTCACGATGACGGCTTT-3’), and hydroxymethylbilane synthase
(hmbs) (primers: FW 5’-GAAACTCTGCTTCGCTGCATT-3’; RW 5’-TGCCCATCTTTCA
TCACTGTATG-3’). The data were analyzed using the comparative Ct method, as described
[26].
Immunofluorescence analysis
Pancreases were cryopreserved and tissue sections were incubated with either anti-MIF (1:100;
#Ab7207, Abcam, Cambridge, UK) or anti-CD74 (1:50; LN-2; #sc-6262, Santa Cruz Biotech-
nology, Inc., Dallas, TE) followed by Alexa Fluor1 488 goat anti-rabbit or mouse IgG (1:500,
Thermo Fisher Scientific/Invitrogen). Next, sections were incubated with anti-F4/80 (1:100;
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clone Cl:A3-1; #MCA497; Bio-rad, Hercules, CA) followed by Alexa Fluor1 555 goat anti-rat
IgG (1:500, Thermo Fisjer Scientific/Invitrogen). Finally, sections were stained with anti-swine
insulin (1:500, #A0564; Dako, Carpinteria, CA) followed by Alexa Fluor1 647 goat anti-guinea
pig IgG (1:750; #106605–003; Jackson ImmunoResearch, West Grove, PA). Slides were coun-
terstained by DAPI and mounted (Dako Faramount Aqueous Mounting Medium, Dako) and
visualized using a Radiance 2001 confocal laser-scanning microscope (Bio-Rad, Hercules,
CA). All acquired images were processed with Fiji/ImageJ software (NIH, Bethesda, MD).
Diabetes intervention
New-onset diabetic splenocytes (1 × 107 cells) were transferred (i.v.) into 6- to 8-week-old
NOD.SCID mice. Alternatively, CD4+ T cells were prepared by negative selection from anti-
gen-primed BDC2.5 TCR Tg NOD splenocytes (1 μg/mL BDC2.5 mimotope for 72 h). Acti-
vated CD4+ T cells (1 × 105) were then transferred into NOD.SCID mice (i.v.). In both transfer
models, the recipient animals were treated i.p. 5 times a week starting from the day of the
transfer with 100 μg ISO-1 or vehicle control. The animals were monitored three times per
week for the development of diabetes.
Isolation and culture of murine peritoneal macrophages
Peritoneal macrophages were collected [27], and preconditioned with 20 μM MIF antagonist
(ISO-1, Sigma) or vehicle control for 24h before overnight culture in the presence or absence
with 10 ng/ml murine recombinant IFN-γ (Peprotech, Rocky Hill, NJ) and 1 μg/ml LPS
(Sigma).
For phenotypic analysis macrophages were seeded in ultra-low attachment plates at 2 × 105
cells per well before preconditioning with ISO-1 and stimulation with LPS/IFN-γ as described
above. Thereafter, 2 × 105 cells were labeled with the following conjugated Abs: F4/80, CD11b,
I-Ad (clone 39-10-8 for NOD), I-Ab (clone AF6-120.1 for C57BL/6), CD86 and matching iso-
type controls (all eBioscience). Non-viable cells were excluded by using the fixable Live/Dead
Yellow stain (Invitrogen). Data acquisition was performed on Gallios™ flow cytometer (Beck-
man Coulter) and the FlowJo™ (Treestar) software was used for data analysis.
Circulating MIF levels and cytokine/chemokine determination
The detection of mouse and human circulating MIF concentrations was done using an anti-
mouse MIF ELISA (R&D Systems, Minneapolis, MN) and a Human MIF ultra-sensitive kit
(MSD, Mesoscale, Rockville, Maryland, MD) respectively. The supernatant of macrophage cul-
tures was analyzed for cytokines/chemokines release using the Mouse Pro-inflammatory Cyto-
kine/Chemokine V-plex kit (MSD; Mesoscale) and the human plasma samples from T1D
patients and age-matched controls were analyzed using the Human Biomarker 30-plex V-plex
kit (MSD; Mesoscale).
Isolation of T cells from TCR Tg mice
Purified T cells were prepared from homogenized splenocytes from Tg mice using magnetic
separation. Briefly, purified total CD4+ T cells (from OT-II–Tg mice or BDC2.5 TCR–Tg
NOD mice) were prepared by negative selection using an Ab cocktail to CD16/CD32, CD11b,
CD11c, B220, MHC class II and CD8 (all eBioscience). Contaminating, bead-bound leukocytes
were removed using goat-anti-rat IgG beads (Dynabeads, Invitrogen).
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In vitro lymphocyte activation assays and flow cytometric analysis
CD4+ lymphocytes from Tg mice were co-cultured with control or ISO-1-treated macrophages
with appropriate peptide (0.1–1 μg/mL) at a 1:10 macrophage / T cell ratio. Macrophage cul-
tures were washed before addition of T cells. The co-cultures were then incubated at 37˚C in
5% CO2 for 3 days before Ab staining and flow cytometric analysis. T cell activation was
assessed by simultaneous staining for CD4, CD44 and CD69 (all eBioscience). Dead cells were
excluded by using the fixable Live/Dead Yellow stain (Invitrogen). Data acquisition was per-
formed on a Gallios™ flow cytometer (Beckman Coulter) and the FlowJo™ (Treestar) software
was used for analysis.
Statistical analysis
Survival analyses with Kaplan-Meier estimates were used to evaluate the difference in the inci-
dence of diabetes onset, with the differences being determined by Mantel-Cox log-rank test
analysis. Groups were analyzed by ANOVA (non-parametric Kruskal-Wallis test) with Dunn’s
multiple comparison or with Mann-Whitney U test, as appropriate (GraphPad Prism software
(Graphpad Prism, La Jolla, CA).
Results
Circulating MIF and its receptor during T1D
To establish a physiological role for the MIF/CD74 pathway in T1D, we verified the expres-
sion of CD74 on circulating monocytes from healthy or (recently diagnosed and long-stand-
ing) T1D subjects. Interestingly classical monocytes of T1D patients (gating as described by
Abeles et al. and depicted in Fig 1A) [25], presented higher surface CD74 expression com-
pared to control subjects (Fig 1B). Investigation of the effector function of classical mono-
cytes based on their ability to produce TNFα in response to activation, revealed that the
majority of the cells displaying effector function, had more abundant surface CD74 expres-
sion (Fig 1C). In turn, we tested the circulating MIF concentrations in T1D patients and age-
matched healthy controls (see S1 Table for patient characteristics). While only some recently
diagnosed and long-standing T1D patients (for less than 10 years) showed elevated MIF con-
centrations, patients with established disease for over 10 years featured significantly higher
MIF concentrations compared to healthy individuals (Fig 1D). Interestingly, circulating MIF
levels positively correlated with disease duration (Spearman r = 0.253; p = 0.0092). Notably,
established T1D patients did not show signs of elevated systemic inflammation as the major-
ity of parameters within the 30-plex cytokine/chemokine biomarker panel were not signifi-
cantly different than the control counterparts (S2 Table). This makes the observation of
elevated MIF concentrations in some patients and particularly in the long-standing T1D
patients potentially relevant. Among the few exceptions to this generalized absence of sys-
temic inflammation was the inflammatory monocyte chemoattractant protein (MCP)-1 (S1
Fig), which was significantly higher in T1D patients than in control subjects. Importantly,
both MIF and MCP-1 have previously demonstrated roles in monocyte/macrophage recruit-
ment and retention [28,29].
We also evaluated circulating MIF concentrations at different disease stages in diabetes-
prone NOD mice. Similar to the human data, significance was only reached in long-standing
diabetic NOD mice compared to non-diabetes-prone control C57BL/6 animals, while the lev-
els detected in other pre-diabetic stages (8-week-old NOD animals) as well as acute diabetics
(12-week-old NOD animals) remained largely unaltered (Fig 1E).
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NOD mice featured increased MIF gene expression and CD74+
leukocyte frequencies in the pancreas
Besides a systemic involvement, we investigated a role for MIF/CD74 pathways locally in the
pancreas. Hereto, moderately elevated MIF and an upward tendency for CD74 gene expression
could be detected in homogenized pancreas material in 12-week-old animals (Fig 2A and 2B).
We further verified the presence of cells expressing protein levels of MIF and its receptor,
CD74, on immunostained sections of cryo-embedded pancreas tissue. Our results indicate
that the source of MIF seems to be originating from multiple cell types within the islets of
Langerhans including, insulin+ β cells and F4/80+ macrophages (Fig 2C) and other studies
implicate also lymphocytes as possible MIF producers [30]. Cells expressing the MIF receptor,
Fig 1. Circulating MIF and monocyte surface CD74 expression during autoimmune diabetes. (A-C) Flow cytometric analysis of human
circulating monocytes from T1D patients was performed as described in the methods section. (A) Contour plot illustrating part of the gating
strategy employed and how the identification of the different monocyte subsets was performed. The plot illustrates the percentage of Classical-,
Intermediate- and Non-classical monocytes based on their expression of CD14 and CD16. (B) Quantification of the mean fluorescence intensity
(MFI) of surface CD74 within the classical monocyte subset. The results represent mean ± SEM (n = 10) (***p0.005). (C) Dot plot indicating
the frequency of classical monocytes producing intracellular TNFα upon activation. Notably, TNFα-positive cells also express high levels of
surface CD74 (n = 10). (D) MIF levels detected in the plasma of healthy controls (open squares) (n = 20), recently diagnosed T1D patients (light
grey squares) (n = 37) or of T1D patients with a disease duration of less than 10 years (dark grey squares) (n = 65) or more than 10 years (black
squares) (n = 36). The symbols represent the individual samples tested (mean ± SEM) (*: p-values 0.05). (E) Circulating MIF levels as
detected by ELISA in control C57BL/6 mice (white bar) (n = 6), pre-diabetic NOD mice (8 weeks) (light grey bar) (n = 10), or diabetic NOD mice
(12 weeks) (dark grey bar) (n = 8) or long-standing diabetic NOD mice (16 weeks and older) (black bar) (n = 4). Results show the mean ± SEM
(*: p-values 0.05).
https://doi.org/10.1371/journal.pone.0187455.g001
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Fig 2. Quantification and visualization of MIF and CD74-expressing cells in the pancreas of NOD
mice. Quantification of the relative MIF and CD74 mRNA levels in the total pancreas of control and NOD mice
by means of real-time reverse transcription PCR (RT-PCR) (Mean ± SEM; n = 4–5) (A &B) (*: p-
values 0.05). (C) Pancreatic sections of NOD mice were stained for insulin (white), MIF (green), F4/80 (red)
and DNA by DAPI (blue) and analyzed with confocal microscopy at ×40 original magnification. Cells featuring
a co-localization of MIF and the macrophage marker F4/80 are indicated by the white arrows. (D) Confocal
microscope image of pancreatic sections of NOD mice were stained for insulin (white), CD74 (green), F4/80
(red) and DNA by DAPI (blue) (×40 original magnification). The images depicted shows one representative
MIF inhibition delays the onset of T1D
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CD74, were present on F4/80+ cells within immune cell infiltrate of the islets of NOD mice
(Fig 2D). CD74+ cells were absent in the pancreas sections of control animals coinciding with
the absence of inflammation (data not shown). Flow cytometric analysis of homogenized pan-
creas revealed that the frequency of F4/80+CD11b+ macrophages in general steadily increased
as NOD mice progress towards disease onset (Fig 2E). Moreover, an upward trend in the fre-
quency of CD74+F4/80+CD11b+ cells in NOD diabetics compared to control mice was
observed (Fig 2F). Besides macrophages and in line with previous work [31], a low abundant
population of CD103+CD11c+ dendritic cells (S2A Fig) as well as a small percentage of lym-
phocytes expressed CD74 (S2B Fig).
MIF antagonism dampened macrophages’ inflammatory response and
expression of molecules involved in antigen presentation
Since NOD macrophages were implicated as one of the possible cell types to respond to the
actions of MIF, we tested whether MIF antagonism could curtail their inflammatory capacity
as well as expression of molecules involved in antigen presentation. As MIF targeting strategy
we used the small molecule ISO-1, which inhibits MIF tautomerase activity by competing with
the substrate for the catalytic site [32]. For this purpose, we pretreated peritoneal mouse mac-
rophages with ISO-1 (20 μM) for 24 hours before exposure to LPS and IFN-γ. In line with pre-
vious findings [8], NOD macrophages produced higher protein levels of IL-6 and CXCL-1
(KC) and an upward tendency for TNFα and MCP-1, compared to non-diabetes-prone con-
trol C57BL/6 counterparts (Fig 3A and 3B). Even in this hyper-inflammatory context, pretreat-
ment of macrophages with ISO-1 successfully counteracted or showed a clear tendency to
dampen the production of the studied inflammatory parameters provoked by activation sti-
muli (Fig 3). In fact, ISO-1 conditioning completely abrogated the production of MCP-1 in
control macrophages, an attribute which could not be completely reproduced in ISO-1-pre-
treated NOD macrophages. Importantly, these ISO-1-mediated effects on macrophage func-
tion could not be attributed to toxicity since we did not observe elevated cell death when
macrophages had been cultured for 24 hours in the presence of the MIF antagonist (S3A Fig).
Taken into account that ISO-1 impeded the macrophage response to inflammatory stimuli,
we tested whether this modulated function would be reflected by the expression levels of mole-
cules involved in antigen presentation. Exposure of either NOD or C57BL/6 peritoneal macro-
phages to ISO-1 prevented the activation-induced upregulation of MHC class II (Fig 4A).
However, for the co-stimulatory molecules CD86 and CD80 this refractory action of ISO-1
was less prominent showing only a marginal inhibition for CD86 (Fig 4B), while the levels of
CD80 were unaltered (data not shown).
Inhibition of MIF delayed the development of diabetes
In order to evaluate the potential in vivo relevance of MIF/CD74 pathway during T1D, we
investigated whether targeting MIF could prevent diabetes transfer by autoimmune NOD sple-
nocytes into NOD.SCID mice. In this experimental model, macrophages are promptly
recruited to the pancreas following T cell transfer where they play a crucial role in amplifying
microphotograph documenting the presence of multiple MIF+- or CD74+ cells within the pancreatic islets of
8-week-old NOD mice. Similar results were obtained with 12-week-old acutely diabetic NOD mice (not
shown). (E) Quantification of the percentage of F4/80+CD11b+ macrophages within the live leukocyte gate
(mean ± SEM; n = 4–5) (*: p-values 0.05). (F) Quantification of the percentage of CD74+ cells within the F4/
80+CD11b+ macrophage population as determined on homogenized pancreas samples by flow cytometry
(mean ± SEM; n = 4–5).
https://doi.org/10.1371/journal.pone.0187455.g002
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Fig 3. Macrophage preconditioning with ISO-1 curtails their activation-induced cytokine and
chemokine production. Peritoneal macrophages isolated from C57BL/6 or NOD mice were purified by
adherence as described and preconditioned with or without ISO-1 before exposure to the activation triggers.
Supernatants were harvested 24 hours after addition of the activation trigger before assessment of cytokines
(A) and chemokines (B) as indicated in the materials and methods section. In an unstimulated condition the
levels of the depicted inflammatory parameters were low to negative (not shown). Data are presented as the
mean ± SEM, (n = 8) (*, p < 0.05; **, p < 0.01, ***p<0.005).
https://doi.org/10.1371/journal.pone.0187455.g003
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T cell activation and acting as effector cells in the attack against the β cells [6,33]. Treatment of
recipient mice with ISO-1 (100 μg/day; 5 times/week; i.p.) significantly delayed autoimmune
diabetes onset (median onset, 4.2±0.3 vs. 5.6±0.4 weeks; Fig 5A). Importantly, also in a very
aggressive variant of this diabetes model, where activated BDC2.5 TCR–Tg CD4+ T cells
(1 × 105) were transferred into NOD.SCID recipients, ISO-1 was successful in significantly
delaying disease onset (median onset, 13±0.8 vs. 21±2.0 days; Fig 5B). ISO-1 treatment of
recipient NOD.SCID animals significantly reduced the frequency of CD74+F4/80+CD11b+
macrophages, as well as in the number of lymphocytes recovered from the pancreas on day 10
post treatment initiation (S4 Fig). Of note, in vivo toxicity of the antagonist was excluded,
since the no significant increase in cell death could be observed in animals treated daily with
the MIF antagonist compared to vehicle-treated controls (S3B Fig).
Inhibition of MIF hampered macrophages’ ability to stimulate T cells
To get more insights into the mechanisms by which ISO-1 interferes with disease pathogenesis,
we assessed the functional impact of ISO-1 treatment of macrophages on T cell activation in
an in vitro system. Hereto, we co-cultured ISO-1-pretreated NOD or C57BL/6 macrophages in
the presence of the corresponding antigen together with CD4+ T cells originated from two
TCR–Tg models: BDC2.5-TCR–Tg NOD mice (expressing a Tg–TCR recognizing I-Ag7–
bound BDC2.5 mimotope in the NOD background) and OT-II–Tg mice (expressing a Tg–
TCR recognizing I-Ab–bound OVA323–339 peptide in the C57BL/6 background) for 72 hours.
Notably in this setup there was no direct contact of the ISO-1 with the T cells as the pre-treated
Fig 4. ISO-1 counteracts the activation-induced expression of MHC class II on control and NOD macrophages. (A)
Surface molecule expression as analyzed by flow cytometry. Macrophages from either control or NOD mice were cultured in the
presence of ISO-1 (20 μM) (dark/black) or vehicle control (light/white), followed by overnight stimulation with or without LPS/IFN-γ
before staining for surface molecules involved in antigen presentation such as MHC class II (A; top row) and the co-stimulatory
molecule CD86 (B; bottom row). Analysis was performed on singlet-, viable-, F4/80+CD11b+ cells. The mean fluorescence
intensity (MFI) is depicted as histogram overlays (left) or bar graphs (right) (n = 4–5). The y-axis indicates the number of cells
analyzed. Values represent the means ± SEM (*, p < 0.05; **, p < 0.01; ***p0.005).
https://doi.org/10.1371/journal.pone.0187455.g004
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macrophages were extensively washed before addition of the peptide prior to addition of T
cells. Corroborating the in vivo data, ISO-1 pre-treated macrophages clearly present a T cell
hypostimulatory capacity compared to untreated control macrophages (Fig 6). This was evi-
denced by the decrease in the level of expression of CD44 and CD69 as indicators of T cell acti-
vation (Fig 6A and 6B). Importantly, these inhibitory actions on T cell activation were
observed for both C57BL/6 and NOD macrophages.
Additional CD4+ T cell subset analysis revealed that naïve T cells defined as
CD44lowCD62Lhigh were markedly increased, whereas the percentages of CD44highCD62Llow
effector T cells and CD44highCD62Lhigh memory T cells were significantly decreased when T
cells had been co-cultured with ISO-1 pretreated macrophages (Fig 6C). These findings sug-
gest that the ISO-1-pretreated macrophages blunt the activation of antigen-specific T cells by
keeping them in a naïve state. Finally, T cells co-cultured with ISO-1-pretreated macrophages
also exhibited an impeded capacity to trigger the effector cytokine, IFN-γ, within the T cell co-
cultures (S5 Fig).
Discussion
MIF is a pleiotropic molecule and a key mediator of many immune processes [11,34,35], and
has been implicated to exacerbate inflammation in several immune disorders [36–40]. In the
context of autoimmune diabetes, older reports have proposed a role for MIF as a contributing
factor in disease pathogenesis in T1D [22, 23, 35, 41]. However, in most cases such a link has
been established by demonstrating resistance of MIF-deficient animals to MLD-STZ challenge
[22,23], whereby a non-specific chemical attack on the β cell is launched. Despite ultimately
inducing hyperglycemia and insulinopenia, this model does not bear strong autoimmune fea-
tures, and as such, it remains highly debatable whether MIF truly contributes to the underlying
mechanisms of the autoimmune attack on the β cell. Here we provide a clear indication that
MIF inhibition can counteract autoimmune diabetes in two different disease transfer models
and provide unique evidence for potential mechanisms which may account for these disease
modifying properties.
Fig 5. Effect of the MIF inhibitor, ISO-1, on the development of diabetes in vivo. (A) Percentage of normoglycemic mice following
the adoptive transfer (i.v.) of splenocytes (1 × 107) isolated from newly-diagnosed diabetic NOD mice into NOD.SCID mice (6–8 week-
old). The recipient animals additionally received ISO-1 (100 μg; i.p.) (grey squares) (n = 9) or vehicle control (black triangles) (n = 12) five
times a week and were monitored twice weekly for the development of diabetes for a total of 10 weeks. (B) Percentage of normoglycemic
mice following the transfer of activated CD4+ T cells from BDC2.5 Tg (1 × 105) mice into NOD.SCID mice. Similarly, the recipient mice
received ISO-1 (100 μg; i.p.) (grey squares) (n = 4) or vehicle control (black triangles) (n = 7) five times a week and were monitored daily
for the development of diabetes. In all panels, statistical significance between groups was determined by Mantel-Cox log-rank test;
*p < 0.05.
https://doi.org/10.1371/journal.pone.0187455.g005
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Along with other novel approaches [41–43], the pharmacologic targeting of MIF either by
monoclonal antibodies or by small molecule antagonists for the treatment of autoimmune dis-
eases has attracted considerable interest and new generation inhibitors are actively investigated
[44,45]. We opted for a well-characterized small molecule MIF antagonist, ISO-1, for a couple
of reasons. ISO-1 binds to the intrinsic tautomerase activity residing in a domain that interacts
with the MIF receptor, CD74 [32,46–48], thus inhibiting both the actions of MIF as well as the
signaling events triggered through CD74. Another potential advantage is its small molecular
size which allows penetration into the cell neutralizing also intracellular MIF effects without
inducing toxicity. However, since ISO-1 only weakly inhibits MIF binding to its receptor and
possibly also because of a higher clearance rate, extremely high doses are needed for in vivo
efficacy. Indeed, Grant et al. failed to delay diabetes development in spontaneous T1D models
with a fluorinated analog of ISO-1, due to dosing or short half-life of the molecule [47]. Other
studies showing successful therapeutic efficacy implemented ISO-1 at unrealistically high
doses of up to 1 mg/mouse/day, which is 10 times higher than the ones used in the current
Fig 6. ISO-1-treated NOD- or C57BL/6-macrophages modulate T cell activation in vitro. (A-C) Ctr- or
ISO-1-treated macrophages isolated from either C57BL/6 or NOD mice (5 × 104 cells/well) were washed
before addition of OVA323-339 peptide or BDC2.5 mimotope (1 μg/mL) and culturing together with negatively
isolated CD4+ T cells from OT-II or BDC2.5 Tg mice (1 × 105 cells/well). The activation status of the co-
cultured T cells was measured by flow cytometric analysis of the mean fluorescence intensity (MFI) of CD44
and CD69 expression on viable CD4+ T cells after 3 days in co-culture (mean ± SEM) (n = 4) (*, p < 0.05; **,
p < 0.01, ***p0.005). (C) To identify naïve T cells (defined as CD44lowCD62Lhigh), memory T cells (defined
as CD44highCD62Lhigh) and effector T cells (CD44highCD62Llow), multi-color flow cytometry was performed
and the frequencies of these populations were quantified. (C) In CD4+ cells, the percentages of effector T cells
significantly decreased in the presence of ISO-1-conditioned macrophages, while naïve T cells remained
prominently visible compared with the control condition. A p-value < 0.05 indicate significant differences
between groups (n = 4). The data shown are representative of four independent experiments.
https://doi.org/10.1371/journal.pone.0187455.g006
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study [22]. Despite the relatively low dose of ISO-1, the antagonist was successful in delaying
diabetes onset in NOD.SCID recipients after adoptive transfer of diabetogenic T cells–models
which are very aggressive and difficult to modulate.
We assessed the functional consequence of MIF inhibition on the ex vivo cytokine response
of NOD macrophages as they have been implicated as the main MIF-responsive cell type.
Indeed, inhibition of MIF binding to CD74 using ISO-1 suppressed the activation-induced
production of pro-inflammatory cytokines (IL-12p40, TNFα, and IL-6) in NOD and control
macrophages. These results are in keeping with the role for MIF as an upstream inflammatory
cytokine, igniting the production of other pro-inflammatory cytokines in macrophages [11].
Besides the promotion cytokine secretion, MIF in combination with CD74 can also promote
leukocyte migration to sites of inflammation via the facilitation of MAPK and PI3K/Akt sig-
naling pathways [49,50]. In our study MIF antagonism counteracted the production of CXCL-
1 (KC) and MCP-1 as respective neutrophil- and monocyte/macrophage attracting chemo-
kines, following exposure of the macrophages to a danger signal. Of particular interest was the
near complete abrogation of MCP-1 expression by the MIF inhibitor. This result is in line with
previous studies implicating MCP-1 as a direct downstream target of MIF/CD74 pathways. In
fact, MIF has been shown to exert its monocyte/macrophage recruitment activities through
MCP-1 induction [29]. Additionally, MCP-1 over-expression in insulin-producing pancreatic
β cells was shown to triggered severe insulitis and diabetes [51]. Upon binding of MIF, CD74
can form functional signal transduction complexes with CD44, CXCR4, and CXCR2 and as
such targeting MIF/CD74 pathways may regulate also numerous other biological activities
[50,52,53]. Although the latter aspects have not been addressed here, it would be highly inter-
esting to determine whether targeting the CXCR4-axis, either directly or indirectly through
CD74, will lead to improved therapeutic efficacy in T1D models. Notably, such strategies have
been shown to be highly effective by the group of Fiorina et al. [54,55].
Unexpectedly, ISO-1-preconditioned C57BL/6 or NOD macrophages showed a potent
capacity to interfere with the activation of OVA-reactive OT-II- or autoreactive BDC2.5 CD4+
T cells in vitro. In both cases pretreatment of macrophages with ISO-1 seemed to prevent
priming of the T cells as the majority of the T cells remain in a naïve status featuring a
CD62LhighCD44low phenotype, while only a small percentage convert into an effector
CD62LlowCD44high phenotype. This reduced capacity of ISO-1-pretreated macrophages to
trigger the transition of naïve T cells to effector T cells was further supported by the impaired
production of IFN-γ, a typical effector cytokine produced by activated Thelper-1 cells. The
ability of ISO-1 to impede T cell priming rather than T cell effector function may partially
explain the moderate disease modifying effect of ISO-1 in the NOD.SCID transfer model, as
the T cells within the donor diabetogenic cells may already exhibit an effector phenotype. Nev-
ertheless, ISO-1 treatment succeeded in triggering a significant delay in the disease onset sug-
gesting at least some inhibitory action also on already activated T cells or their recruitment in
vivo. Although we observed a reduced number pancreatic CD74+ macrophages and lympho-
cytes in NOD.SCID recipient animals following 10 days of ISO-1 treatment, considering the
multifunctional nature of MIF, we cannot exclude that also other mechanisms could be
responsible for the disease modifying properties of MIF observed here.
Tolerance induction by macrophages could include a number of mechanisms, such as the
induction of T cell hyporesponsiveness due to reduced expression of antigen presenting or
costimulatory molecules, T cell silencing or deletion, but also the induction/expansion of regu-
latory T cells (Tregs) or Treg-promoting secreted factors [56–59]. Notably we did not observe
the appearance of CD4+FoxP3+ Tregs or elevated levels of regulatory mediators such as IL-10,
at the end of the three-day co-culture period (data not shown). Within the limits of our assays,
our data revealed that ISO-1 pretreatment prevented the induction of MHC class II as crucial
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parameter involved in the antigen-presentation, while no significant inhibition of co-stimula-
tory molecules CD86 and CD80 could be observed. In this regard, it is important to note that
CD74 has been shown to act as an MHC class II chaperone, which promotes endoplasmic
reticulum exit of MHC class II molecules, directing them to endocytic compartments, prevent-
ing peptide binding in the ER, and contributing to peptide editing in the MHC class II com-
partment. Additionally an accessory role for CD74 was reported during T cell responses
through its interactions with CD44 [60]. It is plausible that inhibition of MIF binding to its
receptor also indirectly affected the normal function of CD74 molecules as participants during
antigen presentation, explaining the impediment of ISO-1 preconditioned macrophages to
trigger T cell activation. Taking this in consideration, an elegant study by Benedek et al., imple-
mented partial MHC complexes loaded with a disease-relevant antigen to inhibit MIF/CD74
downstream signaling, an approach which successfully curtailed disease processes of autoim-
mune encephalomyelitis [61]. Although the approach is promising, additional work is needed
to understand how blocking MIF/CD74 pathways resulted in such profound T cell inhibitory
action.
In summary we provide evidence of elevated MIF levels and the frequency of CD74+ cells
within the islets of diabetic animals and within the circulation of long-standing T1D patients.
Blocking MIF/CD74 pathway not only interfered in disease onset but also hampered macro-
phage cytokine and chemokine responses, supporting a role for MIF as upstream regulator of
innate responses. Strikingly our data also point to a role for MIF in the functional capacity of
macrophages to trigger T cell activation. Such a dual action may proof very effective to inter-
vene in chronic inflammatory diseases and the potential use for MIF neutralizing or antago-
nizing strategies specifically in T1D and potentially also other inflammatory disorders,
warrants further investigation.
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